September is World Alzheimer's Month and this year’s theme is “Time to act on dementia, time to act on Alzheimer’s." ...

Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

Namzaric (donepezil and memantine), also known as MDX-8704, ADS-8704, and Arimenda, is an approved therapy for moderate to severe Alzheimer’s disease. Allergan markets the treatment in the U.S. and ...

Experimental treatments being developed to address the underlying cause of Alzheimer’s disease mostly target beta-amyloid plaques and tau protein tangles, which are thought to be the main players in ...

Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for ...

Treatment with CT1812, previously called Elayta, slowed the decline of cognitive function among adults with mild to moderate Alzheimer’s disease in a proof-of-concept clinical trial dubbed SHINE. That ...

Amylyx Pharmaceuticals‘ investigational oral therapy AMX0035 reduces the levels of several biomarkers associated with Alzheimer’s disease, according to an analysis of data from the PEGASUS trial. “The ...

Someone facing an Alzheimer’s diagnosis may experience a range of emotions, including sadness, anger, and disbelief. It’s hard to tell which is more crippling: the diagnosis itself or the emotional ...